Sanofi Stock

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 09:48:44 2024-07-16 am EDT 5-day change 1st Jan Change
91.92 EUR -0.55% Intraday chart for Sanofi -0.11% +2.42%
Sales 2024 * 46.65B 50.8B Sales 2025 * 49.94B 54.37B Capitalization 116B 126B
Net income 2024 * 7.27B 7.91B Net income 2025 * 8.8B 9.58B EV / Sales 2024 * 2.63 x
Net Debt 2024 * 7.34B 7.99B Net Debt 2025 * 2.97B 3.24B EV / Sales 2025 * 2.37 x
P/E ratio 2024 *
16.9 x
P/E ratio 2025 *
13.9 x
Employees 86,088
Yield 2024 *
4.18%
Yield 2025 *
4.4%
Free-Float 87.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.09%
1 week+0.36%
Current month+2.77%
1 month+6.94%
3 months+5.69%
6 months-2.05%
Current year+2.97%
More quotes
1 week
92.00
Extreme 92
94.91
1 month
85.94
Extreme 85.94
94.91
Current year
84.93
Extreme 84.93
96.50
1 year
80.60
Extreme 80.6
104.32
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 40 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Date Price Change Volume
24-07-16 91.92 -0.55% 244 111
24-07-15 92.43 -2.09% 1,014,293
24-07-12 94.4 +0.63% 1,368,186
24-07-11 93.81 +0.28% 1,211,596
24-07-10 93.55 +1.65% 1,665,730

Real-time Euronext Paris, July 15, 2024 at 11:36 am EDT

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
92.43 EUR
Average target price
108.6 EUR
Spread / Average Target
+17.45%
Consensus